News

PAREXEL's Patient Innovation Center is launched to help sponsors navigate patient centricity from protocol, through study implementation and commercialization access.

Clinical researech technology provider Clinerion and Semicrol, the creator of Fundanet CTMS, will integrate the functionality of Clinerion’s Patient Network Explorer with Semicrol’s CTMS product.

In this study, Clinical Trials Transformation Initiative’s database for aggregate analysis of ClinicalTrials.gov was used to evaluate the number of ongoing and completed interventional clinical trials for various coronary diseases.

Researchers are now looking to design their trials around a bring-your-own-device (BYOD) strategy, which allows participants in a clinical trial to provide study data using their own internet-enabled hardware.

To help combat the nation’s opioid epidemic, FDA is promoting a more tailored approach to developing and testing effective analgesics, with the aim of bringing less addictive pain treatments to market more quickly.

Feasibility, the evaluation of whether a particular trial can recruit enough of the right patients so that the study completes on time and within budget, is arguably the most critical part of the clinical trial process.

A look at current strategies from the industry that address the limitations in clinical trials.

The emergence of CTiD offers the potential to remove future clinical failures much earlier in the process-and pave way for gains in R&D productivity.

Click the title above to open the Applied Clinical Trials September 2018 issue in an interactive PDF format.

To support complex in-home clinical research and investigative sites, well-designed trials must produce the same high-quality data as traditional sites.

Industry experts look at how the specific needs of patients come into play when conducting gene-based screenings.

Alzheimer's Prevention Initiative's discusses a genetic counseling and disclosure model for its Generation Program.

How the use of M&S in cancer trials from the outset can help address those critical “what if?” scenarios and accelerate oncology drug development.

The region is significantly underrepresented in clinical development activity targeting childhood cancer.

Insights on the challenges, activity, and motives in merging bridging research and clinical care.